Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-3112
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
INO-3112 (also known as MEDI0457) is a DNA-based immunotherapy developed by Inovio Pharmaceuticals for the treatment of HPV-associated cancers, including head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The product is a combination of two DNA plasmids: VGX-3100, which encodes the E6 and E7 oncoproteins of Human Papillomavirus (HPV) types 16 and 18, and INO-9012, which encodes human Interleukin-12 (IL-12) to serve as a molecular adjuvant. Delivered via intramuscular injection followed by electroporation using the CELLECTRA device, INO-3112 is designed to induce a robust, antigen-specific CD8+ T-cell response against HPV-infected cells. While previously licensed to MedImmune (a subsidiary of AstraZeneca), the rights were returned to Inovio in 2021, and it continues to be evaluated in Phase 2 clinical trials.
- Other names
- VGX-3100 + INO-9012
02
Targets
IL-12R (Interleukin-12 receptor)HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)Human papillomavirus type 18 protein E7 (HPV18 E7)
Beyond the preview
Go deeper on INO-3112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-3112.